Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motavizumab for Wheezing Prevention in Preterm Infants
NCT00628303Phase 3Withdrawn
- Sponsor
- MedImmune
- Start
- Oct 2010
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of motavizumab in respiratory syncytial virus infection (RSV), sponsored by MedImmune. Planned start Oct 2010; status: withdrawn.
02
Drugs
motavizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00628303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00628303.